[抑郁症和痴呆症的并发症:流行病学,生物学和治疗方面]
1Saint Petersburg State University, St. Petersburg, Russia.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
|December 18, 2024
概括
抑郁症显著增加痴呆症的风险,作为一种因果因素. 了解这种联系对于预防痴呆,包括阿尔茨海默病至关重要.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 老年学是指老年学的学科.
背景情况:
- 抑郁症越来越被认为是认知能力下降的一个重要因素.
- 抑郁症和痴呆症之间的关系需要进一步澄清,以制定有效的预防策略.
研究的目的:
- 审查有关痴呆症和抑郁症之间关系的文献.
- 检查抑郁症作为痴呆症风险因素的作用及其在神经认知障碍中的地位.
- 探索痴呆症和抑郁症相互关系的基础机制.
主要方法:
- 文献综述包括定性研究,元分析和全文文章.
- 在PubMed和谷歌中使用关键词"痴呆症"和"抑郁症"进行的搜索.
主要成果:
- 流行病学和生物学数据表明,抑郁症会增加痴呆风险.
- 有证据支持抑郁症和痴呆症之间存在因果关系的假设.
- 研究了抑郁症在痴呆症神经认知障碍结构中的作用.
结论:
- 抑郁症被证实是痴呆症的重要危险因素.
- 进一步研究抑郁症和痴呆症之间的联系对于预防阿尔茨海默病至关重要.
- 了解抑郁症和痴呆症之间的相互作用可以为公共卫生干预提供信息.
更多相关视频
06:55An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
Published on: December 2, 2015
22.4K
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
601
相关概念视频
Depressive Disorders: Etiology
45
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
45
Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
Depression: Overview
215
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
215
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Depressive Disorders: MDD and Dysthymia
56
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
56
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
